KZR

Kezar Life Sciences, Inc. is a clinical-stage biotechnology company developing novel treatments for autoimmune diseases. The company's lead product candidate, zetomipzomib, is a selective immunoproteasome inhibitor being evaluated for lupus nephritis and other autoimmune conditions. Kezar's approach targets the underlying immune system dysregulation that drives chronic autoimmune diseases, offering potential disease-modifying benefits.